Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

A new study published in Biochemistry sheds light on how bacteria regulate their genes, challenging long-held assumptions ...

Chemical engineers are problem solvers - they bring new medicines to market, develop alternative fuels, keep food manufacturing safe, and create new manufacturing materials. They move small-scale ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells showe how changes in the viral polymerase -- a protein involved in ...

The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...

The Royal Society of Chemistry has agreed a new three-year Open Access publishing agreement with Couperin, a consortium of French Higher Education and Research establishments.

Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

"Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after ...

These patients were separated into 3 groups to receive either sotarasib at a 960 mg dose once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg daily plus panitumumab (53 ...